about
Novel immunotherapeutic approaches to the treatment of urothelial carcinomaEvolving immunotherapy strategies in urothelial cancerContinuous monitoring of enzyme reactions on a microchip: application to catalytic RNA self-cleavage.Case Presentation: Lung Consolidation as Sequelae of BCG Sepsis After Combined Intravesical and Intraurethral BCGNonmuscle invasive bladder cancer: a primer on immunotherapy.Chronic Colovesical Fistula Leading to Chronic Urinary Tract Infection Resulting in End-Stage Renal Disease in a Chronic Granulomatous Disease Patient.Targeted therapies in urothelial carcinoma.Destabilization of phospholipid model membranes by YplA, a phospholipase A2 secreted by Yersinia enterocolitica.Comparative behavior of sterols in phosphatidylcholine-sterol monolayer films.Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer.Lymph node dissection during radical cystectomy following prior radiation therapy: results from the SEER database.Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer.Comparison of postural ergonomics between laparoscopic and robotic sacrocolpopexy: a pilot study.Incorporation of Blood-Clotting Proteins into Phospholipid Langmuir Monolayers: A Fluorescence Microscopy StudyIncorporation of blood clotting factor X into phospholipid model membranes: fluorescence microscopy imaging and subphase effects surrounding the lipid phase transition regionTransplantation of cadaveric pediatric duel en bloc renal allografts in a patient with elevated factor VIII and IX levels
P50
Q26744347-D6C958BA-8D17-4FFC-9AF9-9E5D122B92FFQ26823557-802A70AA-1B64-45B9-ABE5-472C22C0127EQ33209457-407513CF-2100-442E-ADCD-52058339A221Q33715965-9EB5BA95-0A01-4A35-AE05-180C996B6AFFQ37094072-3057E8FD-CA01-4AEF-823B-7BFD6E2FC8F6Q37580720-15900FB8-3B13-45C9-AC87-F7B63D75CA08Q38200798-A3F90D35-FA65-4B3D-80DE-4BC75E9496BFQ41461411-1BA58495-3AAA-468E-A67D-42EEE0645B14Q43564814-C8E8B6A5-CB9E-4876-B48C-086154CE457BQ46349394-9B9039AA-A59F-4866-8709-46DF19745FE0Q47252660-5F7EC811-79B2-4F43-BB93-086517E3AA07Q48029527-0BCD3D81-30D0-49EA-866C-428D259A12B5Q50617796-31BE338D-FFC5-4F47-B18A-15B70810E79FQ73988074-226C875A-3D02-4158-9BB3-4DB8C5346FBCQ79284560-3A803062-EAA2-4BE2-8EA2-592411F78AC0Q80952395-83B93A7F-1105-4B22-8F44-754B29A5512C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sam Brancato
@ast
Sam Brancato
@en
Sam Brancato
@es
Sam Brancato
@sl
type
label
Sam Brancato
@ast
Sam Brancato
@en
Sam Brancato
@es
Sam Brancato
@sl
altLabel
S Brancato
@en
S J Brancato
@en
Sam J Brancato
@en
prefLabel
Sam Brancato
@ast
Sam Brancato
@en
Sam Brancato
@es
Sam Brancato
@sl
P1053
K-3266-2014
P106
P1153
6507564009
P21
P31
P3829
P3835
sam-brancato
P496
0000-0002-3760-5818